| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
34,519,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Co.'s most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. Co. is evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2 clinical trial; and RLYB116, a subcutaneously administered inhibitor of complement factor 5.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$26,050 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
700,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$7,990,000 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Uden Stephen |
See Remarks |
• – – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
709,127 |
709,127 |
|
- |
|
| Mackay Martin |
Chief Executive Officer |
• • – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
436,517 |
436,517 |
|
- |
|
| Mackay Martin |
Chief Executive Officer |
• • – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
272,609 |
272,609 |
|
- |
|
| Fryer Jeffrey M |
See Remarks |
• – – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
709,125 |
201,934 |
|
- |
|
| Parmar Kush |
Director |
– • – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
3,575,340 |
790,714 |
|
- |
|
| Hunt Ronald |
Director |
– • – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,993,911 |
1,993,911 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,694,388 |
1,694,388 |
|
- |
|
| Shannon Timothy M |
Director |
– • – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
2,332,789 |
2,332,789 |
|
- |
|
33 Records found
|
|
Page 2 of 2 |
|
|
